Not Signed In -
Insulin glargine |
insulin glargine [rDNA origin]; Lantus |
Clinical Trial: Insulin Detemir plus Insulin Aspart vs. Insulin Glargine plus Insulin Aspart as Mealtime Insulin in Type II Diabetes
This study is no longer recruiting patients.
|
Purpose
The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type II diabetes.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Diabetes Mellitus, Type II | Drug: insulin detemir Drug: Lantus (insulin glargine) Drug: Novolog (insulin aspart) | Phase III |
MedlinePlus related topics: Diabetes
Study Type: Interventional
Study Design: Treatment, Safety/Efficacy Study
Further Study Details:
Expected Total Enrollment: 300
Study start: September 2004; Study completion: January 2006
Last follow-up: October 2005; Data entry closure: December 2005
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
- Type II diabetics age 18 or older that have had diabetes for at least 12 months.
Location Information
Arkansas
Little Rock, Arkansas, 72204, United States
California
Spring Valley, California, 91978, United States
San Francisco, California, 94143, United States
Inglewood, California, 90301, United States
Santa Ana, California, 92705, United States
Florida
Orlando, Florida, 32804, United States
Melbourne, Florida, 32901, United States
New Port Richey, Florida, 34652, United States
Vero Beach, Florida, 32960, United States
Boca Raton, Florida, 33433, United States
Winter Park, Florida, 32789, United States
Jacksonville, Florida, 32205, United States
Georgia
Athens, Georgia, 30606, United States
Idaho
Idaho Falls, Idaho, 83404, United States
Kansas
Topeka, Kansas, 66606, United States
Nebraska
Omaha, Nebraska, 68131, United States
Nevada
Las Vegas, Nevada, 89119, United States
New Jersey
Berlin, New Jersey, 08009, United States
North Carolina
Asheville, North Carolina, 28801, United States
Pennsylvania
Hermitage, Pennsylvania, 16148, United States
Philadelphia, Pennsylvania, 19107, United States
Texas
Dallas, Texas, 75235, United States
Dallas, Texas, 75246, United States
Dallas, Texas, 75390-8858, United States
San Antonio, Texas, 78229, United States
Virginia
Norfolk, Virginia, 23502, United States
Richmond, Virginia, 23249, United States
Washington
Tacoma, Washington, 98405, United States
More Information
Study ID Numbers: NN304-1431
Record last reviewed: March 2005
Last Updated: March 18, 2005
Record first received: November 17, 2004
ClinicalTrials.gov Identifier: NCT00097084
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: March 2005
Last Updated: March 18, 2005
Record first received: November 17, 2004
ClinicalTrials.gov Identifier: NCT00097084
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Insulin glargine (Drug Digest)
- Lantus (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
